Bextra Plaintiffs Blast Summary Judgment Motion

Law360, New York (April 11, 2008, 12:00 AM EDT) -- As Pfizer Inc. geared up for the first trials in multidistrict litigation over its arthritis drugs Celebrex and Bextra, plaintiffs rebuffed the drug company's bid for summary judgment and defended their use of expert testimony last week.

On Friday, the plaintiffs in the MDL blasted Pfizer's March 31 motion for summary judgment in one of the bellwether cases, brought by Beverly Haslam on behalf of her husband, whose fatal heart attack was allegedly brought on by taking Bextra.

The plaintiffs said Pfizer's “arguments are largely frivolous...
To view the full article, register now.